Key result
Sildenafil therapy linked to ~87% lower odds of sexual dysfunction in women with PAH-CHD.
Why the study?
Sildenafil is frequently prescribed for PAH, but its effects on sexual function in patients with CHD remained poorly studied.
Does sildenafil therapy reduce the occurrence of sexual dysfunction in women with pulmonary arterial hypertension associated with congenital heart disease?
Cohort (n=78)
No
Does sildenafil therapy reduce the occurrence of sexual dysfunction in women with pulmonary arterial hypertension associated with congenital heart disease?
In women with pulmonary arterial hypertension associated with congenital heart disease, sildenafil therapy is independently associated with a significantly lower likelihood of female sexual dysfunction.
Answers are grounded in this paper and cite their sources.
May warrant consideration for sexual dysfunction in PAH-CHD women; hypothesis-generating and requires randomized confirmation.
Globally, approximately 1% of live births are associated with congenital heart disease (CHD), representing the most common congenital abnormality. Roughly 10% of adult CHD patients suffer from pulmonary arterial hypertension (PAH), a condition that may progress to right heart failure and mortality if untreated. Sildenafil is frequently prescribed for PAH; however, its effects on sexual function in patients with CHD remain poorly studied. We performed an observational study employing a retrospective cohort design to evaluate clinical data from patients with CHD treated at Sardjito Hospital, Yogyakarta, between January 2019 and July 2025. Study participants were stratified into two groups, consisting of those receiving sildenafil therapy and those not treated with sildenafil. Eligible participants were required to have been sexually active within the preceding four weeks. Sexual function in both treatment groups was evaluated using the Female Sexual Function Index (FSFI) questionnaire. As many as 78 subjects met the criteria and completed the FSFI questionnaire. Fifty-seven and 21 participants were assigned to the sildenafil-exposed group and to the non-exposed group, respectively. Among those receiving sildenafil, 35.1% (20 patients) experienced sexual dysfunction, while 64.9% (37 patients) had normal sexual function. Bivariate analysis revealed a significant relationship between sildenafil use and sexual dysfunction in the study subjects (p=0.033; 95% CI 0.12-0.94). Multivariate analysis revealed that sildenafil consumption was linked to a lower occurrence of sexual dysfunction (OR 0.13; p=0.005; 95% CI 0.03-0.53). To conclude, sildenafil therapy in women with PAH-CHD was associated with reduced likelihood of sexual dysfunction.
No takes yet. Share an insight, caveat, or question.
Ismawardika et al. (2026) conducted a cohort in Pulmonary arterial hypertension associated with congenital heart disease (n=78). Sildenafil therapy vs. No sildenafil therapy was evaluated on Sexual dysfunction evaluated by the Female Sexual Function Index (FSFI) (OR 0.13, 95% CI 0.03-0.53, p=0.005). Sildenafil therapy in women with PAH-CHD was associated with a reduced likelihood of sexual dysfunction compared to no sildenafil.
Synapse has enriched 10 related papers. Consider them for comparative context: